Figure 5.
TSA treatment leads to a genomic redistribution of H3K9ac, H3K27ac and H3K27me3
(A) Scheme representing the strategy used in Min6 cells.
(B) Number of H3K9ac, H3K27ac and H3K27me3 peaks in vehicle- and TSA-treated Min6 cells.
(C–F) H3K9ac, H3K27ac and H3K27me3 signal in conserved active promoters (C), bivalent promoters (D), poised enhancers (E) and active enhancers (F) in vehicle- and TSA-treated Min6 cells. Heatmaps and mean signals centered on TSS +/−2.5 kb are represented.
See also Figures S3 and S4.
